TY - JOUR
T1 - Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
AU - Norby, Faye
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In this review, we summarize the effectiveness of rivaroxaban versus warfarin and the DOACs dabigatran, apixaban and edoxaban. The primary focus is on primary evidence from clinical trials, indirect comparison studies and real-world studies. While there are gaps in the literature, the evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivaroxaban may be associated with an elevated bleeding risk compared with other DOACs.
AB - Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In this review, we summarize the effectiveness of rivaroxaban versus warfarin and the DOACs dabigatran, apixaban and edoxaban. The primary focus is on primary evidence from clinical trials, indirect comparison studies and real-world studies. While there are gaps in the literature, the evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivaroxaban may be associated with an elevated bleeding risk compared with other DOACs.
UR - http://www.scopus.com/inward/record.url?scp=85032740712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032740712&partnerID=8YFLogxK
U2 - 10.2217/cer-2017-0025
DO - 10.2217/cer-2017-0025
M3 - Article
C2 - 28737102
SN - 2042-6305
VL - 12
SP - 549
EP - 560
JO - Journal of Comparative Effectiveness Research
JF - Journal of Comparative Effectiveness Research
IS - 9
ER -